Try our Advanced Search for more refined results

US Coverage

Law360 Authority | Deep News & Analysis

Global Coverage

Law360 Pulse | The Business of Law

Mealeys

MLex

May 01, 2020

PERIPHAGEN, INC. v. KRYSTAL BIOTECH, INC. et al

View recent docket activity

Reflects complaints, answers, motions, orders and trial notes entered from Jan. 1, 2011.
Additional or older documents may be available in Pacer.

Coverage

  1. March 15, 2022

    Pa. Bio Cos. End Gene Therapy Row In Deal Worth Up To $75M

    Pittsburgh biotech company PeriphaGen Inc. reached a settlement to end litigation alleging its former lab partner, Krystal Biotech Inc., copied its gene therapy technology, with the deal worth at least $25 million and as high as $75 million, Krystal announced Monday.

1 other articles on this case. View all »

Parties

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Direct access to case information and documents.
  • All significant new filings across U.S. federal district courts, updated hourly on business days.
  • Full-text searches on all patent complaints in federal courts.
  • No-fee downloads of the complaints and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

View the parties now

Already a subscriber? Click here to login